Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français
BioSenic - Investors

Investors

Financial Calendar

28 October 2024
Q3 2024 Business and Financial Highlights
30 September 2024
Half Year Results 2024
12 July 2024
Annual General Meeting 2024
06 June 2024
Full Year Results & Annual Report 2023
27 May 2024
Q1 2024 Business and Financial Highlights

This schedule is indicative and subject to change.
The Half-Year Results 2024 have been postponed to 30 September 2024.

BioSenic was formed through a reverse merger between Bone Therapeutics and Medsenic. All financial information can be found below.

Shareholder Information

SHAREHOLDER STRUCTURE

Shareholders structure

SHARE INFORMATION

BioSenic's shares were listed on the regulated market of Euronext Brussels and Euronext Paris on February 6, 2015 under the symbol BIOS.

As of October 2, 2024, BioSenic has a total number of 265.598.531 outstanding shares.

 

BIOS EURONEXT elligible PEA PME

 

ANALYSTS COVERAGE

Portzamparc

Analyst : Clément Bassat

Price Target : 0,52 € on 14/02/2023

 

Gilbert Dupont

Analyst : Pierre-Alexandre Desir

Price Target : 0,21 € on 14/02/2023

 

 

Corporate Governance

Corporate Governance Charter
Dealing Code
Articles of association

IR Contact

Alexia Rieger, CIRO, Chief Investor Relation Officer 

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
investorrelations@biosenic.com

 

Stock information

BioSenic ( BIOS )

0.0017€

20.05.2025

Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions